Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon hospital health management center study 20 (TOPICS 20)

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2952-2960

  Heianza, Yoriko ^a,b   Arase, Yasuji ^b,c   Tsuji, Hiroshi ^b,c   Fujihara, Kazuya ^a   Saito, Kazumi ^a,b,d   Hsieh, Shiun Dong ^b,c   Tanaka, Shiro ^e   Kodama, Satoru ^a,b   Hara, Shigeko ^b,c   Sone, Hirohito ^a,b  

^a NIIGATA UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Okinaka Memorial Institute for Medical Research   (Japan)

^d IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HOSPITALS, PUBLIC; HUMANS; JAPAN; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; YOUNG ADULT;

EID: 84905845347     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4427     Document Type: Article

References (69)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2012;8:228-236.
2. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31:1898-1904.
3. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499-1504.
4. Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86:1020-1025.
5. KarelisAD, St-PierreDH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569-2575.
6. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168:1617-1624.
7. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609-1616.
8. Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring). 2010;18:2354-2361.
9. Samaropoulos XF, Hairston KG, Anderson A, et al. A metabolically healthy obese phenotype in Hispanic participants in the IRAS family study. Obesity (Silver Spring). 2013;21:2303-2309.
10. Naukkarinen J, Heinonen S, Hakkarainen A, et al. Characterising metabolically healthy obesity in weight-discordant monozygotic twins. Diabetologia. 2014;57:167-176.
11. Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24:256-262.
12. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2011;35:971-981.
13. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obes (Lond). 2010;34(suppl 2): S18-S23.
14. Stefan N, Häring H-U, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152-162.
15. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906-2912.
16. Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013;98:2318-2325.
17. Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011;34:61-65.
18. Bo S, Musso G, Gambino R, et al. Prognostic implications for insulin- sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. Am J Clin Nutr. 2012;96: 962-969.
19. Hadaegh F, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F. "Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome?" BMC Public Health. 2011;11:383.
20. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717-722.
21. Appleton SL, Seaborn CJ, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013;36:2388-2394.
22. Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal- weight and metabolically healthy obese individuals. J Clin Endocrinol Metab. 2014;99:462-468.
23. Hwang LC, Bai CH, Sun CA, Chen CJ. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. Asia Pac J Clin Nutr. 2012;21:227-233.
24. Kim CH, Kim HK, Bae SJ, Kim EH, Park JY. Independent impact of body mass index and metabolic syndrome on the risk of type 2 diabetes in Koreans. Metab Syndr Relat Disord. 2012;10:321-325.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69.
26. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3: 8-10.
27. The International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. 2006. http://www.idf.org/webdata/docs/IDF- Meta-def-final.pdf.
28. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27: 157-172; discussion 207-112.
29. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483-495.
30. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diag1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2012;8:228-236.
31. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31:1898-1904.
32. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499-1504.
33. Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86:1020-1025.
34. KarelisAD, St-PierreDH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569-2575.
35. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168:1617-1624.
36. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609-1616.
37. Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring). 2010;18:2354-2361.
38. Samaropoulos XF, Hairston KG, Anderson A, et al. A metabolically healthy obese phenotype in Hispanic participants in the IRAS family study. Obesity (Silver Spring). 2013;21:2303-2309.
39. Naukkarinen J, Heinonen S, Hakkarainen A, et al. Characterising metabolically healthy obesity in weight-discordant monozygotic twins. Diabetologia. 2014;57:167-176.
40. Sung KC, Cha SC, Sung JW, So MS, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24:256-262.
41. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2011;35:971-981.
42. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obes (Lond). 2010;34(suppl 2): S18-S23.
43. Stefan N, Häring H-U, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152-162.
44. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906-2912.
45. Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013;98:2318-2325.
46. Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011;34:61-65.
47. Bo S, Musso G, Gambino R, et al. Prognostic implications for insulin- sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. Am J Clin Nutr. 2012;96: 962-969.
48. Hadaegh F, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F. "Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome?" BMC Public Health. 2011;11:383.
49. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717-722.
50. Appleton SL, Seaborn CJ, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013;36:2388-2394.
51. Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal- weight and metabolically healthy obese individuals. J Clin Endocrinol Metab. 2014;99:462-468.
52. Hwang LC, Bai CH, Sun CA, Chen CJ. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. Asia Pac J Clin Nutr. 2012;21:227-233.
53. Kim CH, Kim HK, Bae SJ, Kim EH, Park JY. Independent impact of body mass index and metabolic syndrome on the risk of type 2 diabetes in Koreans. Metab Syndr Relat Disord. 2012;10:321-325.
54. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69.
55. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3: 8-10.
56. The International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. 2006. http://www.idf.org/webdata/docs/IDF- Meta-def-final.pdf.
57. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27: 157-172; discussion 207-112.
58. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483-495.
59. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagdoi: 10.1210/jc.2013-4427 jcem.endojournals.org 2959 The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 August 2014. at 06:00 For personal use only. No other uses without permission. . All rights reserved. nostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649.
60. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29:939-960.
61. Stefan N, Haring HU. The metabolically benign and malignant fatty liver. Diabetes. 2011;60:2011-2017.
62. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. 2014;15(6):504-515.
63. Jung HS, Chang Y, Yun KE, et al. Impact of body mass index, metabolic health, and weight change on incident diabetes in a Korean population [published online April 4, 2014]. Obesity (Silver Spring). doi: 10.1002/oby.20751.
64. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study [published online March 26, 2014]. Eur Heart J. doi: 10.1093/eurheartj/ehu123.
65. Kantartzis K, Machann J, Schick F, et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia. 2011;54:864-868.
66. Janiszewski PM, Ross R. Effects of weight loss among metabolically healthy obese men and women. Diabetes Care. 2010;33:1957- 1959.
67. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med. 2013;159:758-769.
68. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-728.
69. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a metaanalysis. Hepatology. 2011;54:1082-1090.